Heather Ledbetter Prichard net worth and biography

Heather Prichard Biography and Net Worth

COO of Humacyte

Dr. Prichard’s overall responsibility is translating the company’s innovative mission, vision and strategies into actionable activities. She brings over 20 years of strong leadership experience in the fields of tissue engineering, extracellular matrix biology, and biological response to implantable biomaterials.

What is Heather Ledbetter Prichard's net worth?: The estimated net worth of Heather Ledbetter Prichard is at least $3.41 thousand as of May 30th, 2024. Dr. Prichard owns 2,625 shares of Humacyte stock worth more than $3,413 as of December 4th. This net worth estimate does not reflect any other assets that Dr. Prichard may own. Additionally, Dr. Prichard receives an annual salary of $647,780.00 as COO at Humacyte. Learn More about Heather Ledbetter Prichard's net worth.
How old is Heather Ledbetter Prichard?: Dr. Prichard is currently 46 years old. There are 5 older executives and no younger executives at Humacyte. The oldest executive at Humacyte is Mr. Dale A. Sander, CFO, Chief Corporate Development Officer & Treasurer, who is 64 years old. Learn More on Heather Ledbetter Prichard's age.
What is Heather Ledbetter Prichard's salary?: As the COO of Humacyte, Inc., Dr. Prichard earns $647,780.00 per year. There are 2 executives that earn more than Dr. Prichard. The highest earning executive at Humacyte is Dr. Laura E. Niklason M.D., Ph.D., Founder, President, CEO & Director, who commands a salary of $899,250.00 per year. Learn More on Heather Ledbetter Prichard's salary.
How do I contact Heather Ledbetter Prichard?: The corporate mailing address for Dr. Prichard and other Humacyte executives is 1177 AVENUE OF THE AMERICAS 5TH FLOOR, NEW YORK NY, 10036. Humacyte can also be reached via phone at 919-313-9633 and via email at [email protected]. Learn More on Heather Ledbetter Prichard's contact information.
Has Heather Ledbetter Prichard been buying or selling shares of Humacyte?: Heather Ledbetter Prichard has not been actively trading shares of Humacyte over the course of the past ninety days. Most recently, Heather Ledbetter Prichard sold 188,886 shares of the business's stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $8.14, for a transaction totalling $1,537,532.04. Following the completion of the sale, the chief operating officer now directly owns 2,625 shares of the company's stock, valued at $21,367.50. Learn More on Heather Ledbetter Prichard's trading history.
Who are Humacyte's active insiders?: Humacyte's insider roster includes Michael Constantino (Director), Brady Dougan (Director), Laura Niklason (CEO), Shamik Parikh (Chief Medical Officer), Heather Prichard (COO), Dale Sander (CFO), William Scheessele (Chief Commercial Officer), and Kathleen Sebelius (Director). Learn More on Humacyte's active insiders.
Are insiders buying or selling shares of Humacyte?: During the last twelve months, Humacyte insiders bought shares 5 times. They purchased a total of 88,593 shares worth more than $138,418.22. During the last twelve months, insiders at the sold shares 6 times. They sold a total of 4,482,090 shares worth more than $7,466,382.20. The most recent insider tranaction occured on August, 20th when Director Brady W Dougan sold 591,685 shares worth more than $934,862.30. Insiders at Humacyte own 5.1% of the company. Learn More about insider trades at Humacyte.
Information on this page was last updated on 8/20/2025.

Heather Ledbetter Prichard Insider Trading History at Humacyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/30/2024	Sell	188,886	$8.14	$1,537,532.04	2,625
5/25/2023	Sell	9,613	$3.83	$36,817.79	64,566

Heather Ledbetter Prichard Buying and Selling Activity at Humacyte

Humacyte Company Overview

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Today's Range

Now: $1.30

$1.26

$1.33

50 Day Range

MA: $1.53

$1.12

$2.48

2 Week Range

Now: $1.30

$1.09

$6.77

Volume

3,077,595 shs

Average Volume

4,793,646 shs

Market Capitalization

$243.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.9

Heather Prichard Biography and Net Worth

What is Heather Ledbetter Prichard's net worth?

How old is Heather Ledbetter Prichard?

What is Heather Ledbetter Prichard's salary?

How do I contact Heather Ledbetter Prichard?

Has Heather Ledbetter Prichard been buying or selling shares of Humacyte?

Who are Humacyte's active insiders?

Are insiders buying or selling shares of Humacyte?